HeartFlow (HTFL)

Executive Summary

HeartFlow is a commercial-stage AI-powered medical technology company transforming coronary artery disease (CAD) diagnosis with its non-invasive FFRCT analysis platform. The company's SaMD converts standard CCTA scans into 3D cardiac models, enabling precise assessment of coronary anatomy and physiology. Deployed across 1,800+ institutions and used in over 600,000 patients, HeartFlow has established itself as a standard of care in CAD management. The platform's clinical utility and cost-effectiveness continue to drive adoption, supported by strong intellectual property and FDA clearances. However, competition from emerging AI diagnostics and potential reimbursement headwinds pose risks. Overall, HeartFlow is well-positioned for sustained growth in the expanding non-invasive cardiovascular diagnostics market.

Upcoming Catalysts (preview)

• Q3 2026FDA clearance of next-generation FFRCT algorithm85% success
• H2 2026Expansion into Chinese market through strategic partnership60% success
• Q4 2026Positive results from ongoing clinical trial (e.g., PRECISE)70% success